Supplementary Files
Keywords
Solifenacin
Mirabegron
Anticholinergics
How to Cite
Abstract
Objective: Overactive bladder (OAB) is a common condition characterized by urinary urgency, frequency, and incontinence. Anticholinergics, beta-3 agonists, and mirabegron are commonly used to manage OAB symptoms. Anticholinergics are effective but may cause side effects such as dry mouth, constipation, and drowsiness. Beta-3 agonists, like Mirabegron, are a viable option for individuals seeking to avoid these side effects.
Methods: A study of 45 female patients with OAB symptoms was conducted to evaluate the effectiveness of two cross-over protocols. Group A received mirabegron followed by solifenacin, and group B received mirabegron followed by solifenacin.
Results: The results showed that both treatments were effective in reducing the symptoms of OAB as measured by the IPSS, OABSS, and VAS scores for emergency and distention. The side effects of dry mouth and constipation were relatively mild. However, a p-value of 0.007 shows that there was no significant difference in effectiveness and side effects between the two groups.
Conclusion: Both treatment options can be effective for OAB, but each has specific disadvantages. Consulting with a healthcare provider is important to determine the best treatment option based on an individual's specific needs and medical history.
Keywords: Overactive bladder, Solifenacin, Mirabegron, Anticholinergics.
References
Malone‐Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU international. 2003 Sep;92(4):415-7.
Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000 Jul 1;6(11 Suppl):S574-9.
Shy M, Fletcher SG. Objective evaluation of overactive bladder: which surveys should I use?. Current bladder dysfunction reports. 2013 Mar;8:45-50.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study. BJU international. 2001 Jun;87(9):760-6.
Coyne KS, Cash B, Kopp Z, Gelhorn H, Milsom I, Berriman S, Vats V, Khullar V. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU international. 2011 Jan;107(2):254-61.
Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Canadian Urological Association Journal. 2015 Sep;9(9-10):343.
Bragg R, Hebel D, Vouri SM, Pitlick JM. Mirabegron: a beta-3 agonist for overactive bladder. The Consultant Pharmacist®. 2014 Dec 1;29(12):823-37.
Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Therapeutic advances in drug safety. 2016 Oct;7(5):204-16.
Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nature Reviews Urology. 2021 Nov;18(11):686-700.
Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews. 2007(3).
Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clinical therapeutics. 2013 Nov 1;35(11):1744-51.
Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clinical therapeutics. 2005 Feb 1;27(2):144-53.
Araklitis G, Robinson D, Cardozo L. Cognitive effects of anticholinergic load in women with overactive bladder. Clinical Interventions in Aging. 2020 Aug 25:1493-503.
Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Research and reports in urology. 2013 Dec 6:1-6.
Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004 Aug;64:1643-56.
Çetinel B, Onal B. Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean Journal of Urology. 2013 Dec 1;54(12):806-15.
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018 Oct;17(3):341-56.
Khawam EA, Laurencic G, Malone Jr DA. Side effects of antidepressants: an overview. Cleveland Clinic journal of medicine. 2006 Apr 1;73(4):351.
Gleicher S, Sebesta EM, Reynolds WS, Dmochowski R. Vibegron for the treatment of overactive bladder: a comprehensive update. Expert Opinion on Pharmacotherapy. 2022 Sep 2;23(13):1479-84.
Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Therapeutic advances in drug safety. 2016 Oct;7(5):204-16.
Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Current medical research and opinion. 2016 Apr 2;32(4):621-38.
Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. European urology. 2003 Aug 1;44(2):165-74.
Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. European urology. 2004 Apr 1;45(4):510-5.
Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourology and urodynamics. 2014 Jan;33(1):17-30.
Bhide AA, Digesu GA, Fernando R, Khullar V. Use of mirabegron in treating overactive bladder. International urogynecology journal. 2012 Oct;23:1345-8.
Makhani A, Thake M, Gibson W. Mirabegron in the treatment of overactive bladder: safety and efficacy in the very elderly patient. Clinical interventions in aging. 2020 Apr 23:575-81.
Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. European urology. 2014 Apr 1;65(4):755-65.
Inoue M, Yokoyama T. Comparison of two different drugs for overactive bladder, solifenacin and mirabegron: A prospective randomized crossover study. Acta Medica Okayama. 2019;73(5):387-92.
Simpson D, Wagstaff AJ. Solifenacin in overactive bladder syndrome. Drugs & aging. 2005 Dec;22:1061-9.
Nitti VW, Khullar V, Van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies. International journal of clinical practice. 2013 Jul;67(7):619-32.
Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. European urology. 2016 Feb 1;69(2):311-23.
Kobayashi M, Nukui A, Kamai T. Comparative efficacy and tolerability of antimuscarinic agents and the selective β3‐adrenoceptor agonist, mirabegron, for the treatment of overactive bladder: which is more preferable as an initial treatment?. LUTS: Lower Urinary Tract Symptoms. 2018 May;10(2):158-66.Table 1: Pre-administration background information for the 45 patients.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2023 Nazish Sarfraz, Humera Akram, Afroza Abbas, Sadaf Shaheen, Zoobia Ashiq Awan, Eesha Yaqoob